COMP <GO>
GDTC vs GTBP // RETURN ON INVESTED CAPITAL (ROIC)
CytoMed Therapeutics Limited (NASDAQ) VS. GT Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: GDTC 1
— GTBP 2
■ METRIC PARITY
LAST: $0.91 (-0.98%) • MKT CAP: $10.9M
roic
—
LAST: $5.13 (-3.57%) • MKT CAP: $11.0M
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GDTC VS. GTBP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GDTC | GTBP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.98% | -1.98 | GTBP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.9 | 42.0 | +9.90 | GDTC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.9M | $11.0M | -$96.8K | GTBP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GDTC REV | GTBP REV | GDTC GROSS % | GTBP GROSS % | GDTC FCF | GTBP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $34.8M | — | — | — | -$12.9M |
| FY 2024 | — | $40.2M | — | — | — | -$12.9M |
| FY 2023 | — | $38.0M | — | — | — | -$8.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GDTC // BETA —
GTBP // BETA —